CYP2D6.

In this book of nine chapters, expert authors explore the properties of CYP2D6 with respect to the basic genetic aspects, its interactions with drugs that are substrates and/or inhibitors, and the implications of the pharmacogenetics of CYP2D6 in the clinical context.

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Baumann, Pierre
Formato: Electrónico eBook
Idioma:Inglés
Publicado: London : Future Science Group, 2014.
Temas:
Cytochrome P-450 > Physiological effect.
Cytochrome P-450 > Genetics.
Cytochrome P-450 > Therapeutic use.
Cytochrome P-450 > Effets physiologiques.
Cytochrome P-450 > Génétique.
Cytochrome P-450 > Emploi en thérapeutique.
Cytochrome P-450 > Physiological effect
Acceso en línea:Texto completo
Tabla de Contenidos:
  • CYP2D6: genetics, pharmacology and clinical relevance
  • A history and overview of phenotypic variability in CYP2D6 activity
  • Genetic variability of CYP2D6: basic and clinical aspects
  • CYP2D6: interethnic variability
  • CYP2D6 ethnic variability in Hispanics
  • Structural properties of CYP2D6: requirements for substrates and inhibitors
  • CYP2D6 substrates and drug metabolism
  • _GoBack
  • _ENREF_1
  • _ENREF_2
  • _ENREF_3
  • _ENREF_4
  • _GoBack
  • _ENREF_1
  • _ENREF_2
  • _ENREF_3
  • _ENREF_4
  • _ENREF_5
  • _ENREF_6
  • _ENREF_7
  • _ENREF_8
  • _ENREF_9_ENREF_10
  • _ENREF_11
  • _ENREF_12
  • _ENREF_13
  • _ENREF_14
  • _ENREF_15
  • _ENREF_16
  • _ENREF_17
  • _ENREF_18
  • _ENREF_19
  • _ENREF_20
  • _ENREF_21
  • _ENREF_22
  • _ENREF_23
  • _ENREF_24
  • _ENREF_25
  • _ENREF_26
  • _ENREF_27
  • _ENREF_28
  • _ENREF_29
  • _ENREF_30
  • _ENREF_31
  • _ENREF_32
  • _ENREF_33
  • _ENREF_34
  • _ENREF_35
  • _ENREF_36
  • _ENREF_38
  • _ENREF_39
  • _ENREF_40
  • _ENREF_41
  • _ENREF_42
  • _ENREF_43
  • _ENREF_44
  • _ENREF_45
  • OLE_LINK1
  • OLE_LINK2
  • OLE_LINK5
  • OLE_LINK6
  • OLE_LINK3OLE_LINK2
  • OLE_LINK1
  • OLE_LINK28
  • OLE_LINK27
  • OLE_LINK30
  • OLE_LINK29
  • OLE_LINK32
  • OLE_LINK31
  • OLE_LINK34
  • OLE_LINK33
  • OLE_LINK36
  • OLE_LINK35
  • OLE_LINK38
  • OLE_LINK37
  • OLE_LINK24
  • OLE_LINK23
  • OLE_LINK40
  • OLE_LINK39
  • OLE_LINK42
  • OLE_LINK41
  • OLE_LINK44
  • OLE_LINK43
  • OLE_LINK46
  • OLE_LINK45
  • OLE_LINK48
  • OLE_LINK47
  • _GoBack
  • OLE_LINK9
  • OLE_LINK8
  • OLE_LINK7
  • OLE_LINK13
  • OLE_LINK12
  • OLE_LINK22
  • OLE_LINK15
  • OLE_LINK14
  • OLE_LINK11
  • OLE_LINK10
  • OLE_LINK17OLE_LINK16
  • OLE_LINK19
  • OLE_LINK18
  • _GoBack
  • OLE_LINK2
  • OLE_LINK3
  • Molecular mechanism of CYP2D6-mediated oxidation
  • Substrate binding to CYP2D6 active site
  • CYP2D6 substrates that are commercially available drugs
  • Implications of variability in exposure to CYP2D6 substrates
  • Modeling of CYP2D6 genotype-related variability in the pharmacokinetics of CYP2D6 substrates
  • Assessment of CYP2D6-mediated elimination in the early stages of drug development
  • _GoBack
  • _GoBack
  • _ENREF_1
  • _ENREF_2
  • _ENREF_3
  • _ENREF_4
  • _ENREF_5_ENREF_6
  • _ENREF_7
  • _ENREF_8
  • _ENREF_9
  • _ENREF_10
  • _ENREF_11
  • _ENREF_12
  • _ENREF_13
  • _ENREF_14
  • _ENREF_15
  • _ENREF_16
  • _ENREF_17
  • _ENREF_18

Ejemplares similares